Trial Profile
A Sponsor Un-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat, Ascending Doses of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2798745 (Primary) ; GSK 2798745 (Primary) ; GSK 2798745 (Primary)
- Indications Heart failure; Pulmonary oedema
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
- 14 Jan 2019 Results evaluating the safety, tolerability, and pharmacokinetics of single and repeat oral doses of GSK2798745 administered to healthy subjects and patients with stable heart failure published in the American Journal of Cardiovascular Drugs
- 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development
- 20 Jan 2017 Status changed from recruiting to completed.